NEW YORK, NY, Axon Therapies, a clinical-stage medical device company pioneering a new approach to treating heart failure, has announced the close of an oversubscribed $32 million Series A financing.
The round was co-led by new investors Earlybird Venture Capital and Santé Ventures, with participation by existing investor Deerfield Management and new investors CD Capital and KOFA Healthcare.
Axon Therapies is a private MedTech company developing minimally invasive therapies that address the root causes of heart failure. Its lead innovation, SAVM using the Satera™ Ablation System, enables targeted ablation of the overactive sympathetic nervous system without the need for an implant.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
